REG - Alliance Pharma PLC - Block Listing Six Monthly Return

Alliance PharmaAnnouncement

02/01/2024 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240102:nRSB3666Ya&default-theme=true

RNS Number : 3666Y  Alliance Pharma PLC  02 January 2024

 

 For immediate release  02 January 2024

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Block Listing Six Monthly Return

 

 Name of applicant:                                                              ALLIANCE PHARMA PLC
 Names of schemes:                                                               a)     The Alliance Pharma plc Approved Share Option Plan 2005

                                                                                 b)    The Alliance Pharma plc Share Option Plan 2006

                                                                                 c)     The Alliance Pharma plc Company Share Option Plan 2015

                                                                                 d)    The Alliance Pharma plc Long-Term Incentive Plan 2019
 Period of return:                       From:                                   28 June 2023             To:                      31 December 2023
 Number of securities originally admitted at date of admission:                  25,000,000 ordinary shares of 1p each

                                                                                 28 June 2017
 Balance of unallotted securities under schemes from previous return:            a)     57,922

                                                                                 b)    2,487,746

                                                                                 c)     9,572,622

                                                                                 d)    1,341,116
 Plus:  The amount by which the block schemes have been increased since the      a)     Nil
 date of the last return (if any increase has been applied for):

                                                                                 b)    Nil

                                                                                 c)     Nil

                                                                                 d)    Nil
 Less:  Number of securities issued/allotted under schemes during period:        a)  0

                                                                                 b) 14,239

                                                                                 c)  0

                                                                                 d) 225,618

 Equals:  Balance under schemes not yet issued/allotted at end of period:        a)    57,922

                                                                                 b)    2,473,507

                                                                                 c)     9,572,622

                                                                                 d)    1,115,498

 

 Name of contact:              Chris Chrysanthou, Company Secretary
 Telephone number of contact:  Tel. +44 (0)1249 705166

 

 

 

 

For further information:

 

 Alliance Pharma plc                                                     + 44 (0)1249 466966
 Head of Investor Relations: Cora McCallum                               + 44 (0)1249 705168
 ir@allianceph.com (mailto:ir@allianceph.com)

 Buchanan                                                                + 44 (0)20 7466 5000
 Mark Court / Sophie Wills
 alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)

 Deutsche Numis (Nominated Adviser and Joint Broker)                     + 44 (0)20 7260 1000
 Nominated Adviser: Freddie Barnfield / Duncan Monteith / Sher Shah

 Investec Bank plc (Joint Broker)                                        + 44 (0)20 7597 5970
 Patrick Robb / Maria Gomez de Olea

 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our
purpose is to empower people to make a positive difference to their health and
wellbeing by making our trusted and proven brands available around the world.

 

We deliver organic growth through investing in our priority brands and
channels, in related innovation, and through selective geographic expansion to
increase the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary acquisitions.

 

Headquartered in the UK, the Group employs around 285 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics we remain asset-light and focused
on maximising the value we can bring, both to our stakeholders and to our
brands. For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRUUSRRSNUARAR